Skip to main content

Cotellic News

New Hope Against a Rare, Aggressive Form of Thyroid Cancer

MONDAY, Oct. 28, 2024 – Most thyroid cancers are slow-moving and, if caught early, curable. But some patients can present with what's known as an anaplastic thyroid carcinoma (ATC) – a rare and...

FDA Approves Oral MEK Inhibitor Cobimetinib for Histiocytic Neoplasms, Research Led by Memorial Sloan Kettering Cancer Center

1-Nov-2022 – Memorial Sloan Kettering Cancer Center (MSK) announced today that the U.S. Food and Drug Administration (FDA) has approved the oral MEK inhibitor drug cobimetinib (Cotellic®) for the t...

FDA Approves Cotellic (cobimetinib) for the Combination Treatment of Advanced Melanoma

November 10, 2015 – The U.S. Food and Drug Administration today approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Cotellic patient information at Drugs.com